Literature DB >> 19437363

Health-related quality of life (HRQL) in all-patients treated with chemotherapy only: a report from the late effects surveillance system in Germany.

J Peeters1, J Meitert, M Paulides, A Wiener, J D Beck, G Calaminus, T Langer.   

Abstract

BACKGROUND: The study examines the HRQL in children suffering from ALL over time. PATIENTS: 96 patients (average age 7.1 years) were included, treated with chemotherapy in 15 German study centres between 1997 and 2003.
METHODS: The HRQL was assessed based on both the parent report (POQOLS) and the patient self-report (KINDL) at 3 intervals: up to 2 weeks after diagnosis (T1), upon completion of the re-induction therapy (T2) and at the end of the maintenance therapy (T3). To analyse the changes of HRQL over time, the differences between the individual scores (T2-T1 and T3-T1) were calculated and statistically tested. The HRQL results from KINDL were also compared to a sample from the German general population.
RESULTS: POQOLS (scale 0 (optimum) to 6): A decrease of HRQL was found in the domain "activity" at T1 (mean score=3.1) and T2 (mean score=2.6). Over time, HRQL improved significantly with a mean score-difference T3-T1=-0.7 (p=0.001). KINDL (scale 0 to 100 (optimum)): The individual HRQL-scores improved over time with the major increases occurring in the domains "physical" with a mean score-difference T2-T1=21.7 (p<0.0001) and a mean score-difference T3-T1=20.6 (p=0.0002) and "mental" with a mean score-difference T2-T1=7.1 (p=0.02) and T3-T1=8.1 (p=0.02). However, the mean overall HRQL-score was significantly lower compared to the general population.
CONCLUSIONS: Children with ALL show lower HRQL compared to the general population. Over time, HRQL improved significantly from both the patient and the parent perspective.

Entities:  

Mesh:

Year:  2009        PMID: 19437363     DOI: 10.1055/s-0029-1216366

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  4 in total

1.  Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.

Authors:  Joanna Peeters; Johannes Meitert; Marios Paulides; Jörn D Beck; Thorsten Langer
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

2.  Health-related quality of life in paediatric patients up to five years post-treatment completion for acute lymphoblastic leukaemia: a systematic review.

Authors:  Andrew Garas; Louise A McLean; Cinzia R De Luca; Peter Downie; Maria C McCarthy
Journal:  Support Care Cancer       Date:  2019-03-21       Impact factor: 3.603

3.  Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia.

Authors:  Raphaële R L van Litsenburg; Jaap Huisman; Rob Pieters; Chris Verhaak; Gertjan J L Kaspers; Reinoud J B J Gemke
Journal:  Support Care Cancer       Date:  2014-07-11       Impact factor: 3.603

4.  Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia.

Authors:  Clarissa E Schilstra; Karen McCleary; Joanna E Fardell; Mark W Donoghoe; Emma McCormack; Rishi S Kotecha; Richard De Abreu Lourenco; Shanti Ramachandran; Ruelleyn Cockcroft; Rachel Conyers; Siobhan Cross; Luciano Dalla-Pozza; Peter Downie; Tamas Revesz; Michael Osborn; Frank Alvaro; Claire E Wakefield; Glenn M Marshall; Marion K Mateos; Toby N Trahair
Journal:  BMC Cancer       Date:  2022-09-15       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.